Eli Lilly, the maker of Zepbound and Mounjaro, had pushed back against the OFAs assertion that shortages of tirzepatide were still in place, and has also claimed that versions of the drug made by compounded pharmacies are often untested, unapproved knockoffs, according to NBC News
Important context for emerging research: GLP-1 research may eventually inform future understanding of overlapping reward pathways Current evidence does not support GLP-1s as a treatment for co-occurring conditions GLP-1 medications are not part of existing evidence-based treatment pathways At this time, specialized, integrated care remains the standard for treating co-occurring eating disorders and substance use disorders
Diets help, but patients know, if you were losing weight, I hate to say it, they probably wouldnt be going for the GLP-1s typically
Benefits of Using a Peptide Calculator Did you know the benefits you get from using the Peptide calculator